ORG – Page 3 – Talk Bio

Takeda’s Phase 3 Success Positions Oveporexton (TAK-861) as Potential First Mover in Multibillion-Dollar Narcolepsy Market

3 days ago talkbio0Tagged Clinical Trials, multibillion-dollar market, Narcolepsy type 1, oveporexton, Phase 3, Standard of Care, TAK-861, Takeda, TPRG1L gene

Takeda; Phase 3; narcolepsy type 1; oveporexton; TAK-861; orexin agonist; multibillion-dollar market; clinical trial results; first mover; standard of care

Rapport Reveals Promising Phase 2a Data for RAP-219 Epilepsy Pill, Plans Phase 3 Trials

3 days ago talkbio0Tagged anti-seizure medication, Clinical Development, drug-resistant epilepsy, Epilepsy, focal onset seizures, RAP-219, Rapport Therapeutics, Seizures

Rapport Therapeutics; RAP-219; epilepsy; seizure reduction; Phase 2a clinical trial; focal onset seizures; Phase 3 trials; anti-seizure medication; drug-resistant epilepsy; clinical development

Junshi Biosciences Announces Phase 3 Win for IL-17A Drug JS005 in Psoriasis, Prepares China NDA Submission

3 days ago talkbio0Tagged Biosciences, China, clinical endpoints, Drug Approval, IL-17A monoclonal antibody, JS005, Junshi, Psoriasis

Junshi Biosciences; JS005; IL-17A monoclonal antibody; psoriasis; phase 3 trial; clinical endpoints; China drug approval

IQVIA Laboratories Bioinformatics Solutions Accelerate Genomic Insights for Drug Discovery in Partnership with NVIDIA

3 days ago talkbio0Tagged AI agents, Aortic Valve Insufficiency, Bio-Informatics, Drug Discovery, Enterprise, Genome, Genomics, IQVIA, NVIDIA, Precision Medicine

IQVIA; Genomic Insights; Bioinformatics; Drug Discovery; NVIDIA; AI Agents; Genomics; Precision Medicine; AI Enterprise; E360 Genomics

FDA Shifts Approach on GLP-1 Compounding: Announces Consumer Green List Instead of Immediate Crackdown

3 days ago talkbio0Tagged Compound, Consumer Safety, Drug shortages, Glucagon-Like Peptide 1, green list, import alert, Regulation, semaglutide, United States Food and Drug Administration

FDA; GLP-1; compounding; green list; drug shortages; semaglutide; tirzepatide; import alert; consumer safety; regulation

BioNTech and DualityBio Achieve Phase 3 Success with ADC Therapy for HER2-Positive Breast Cancer, Advancing Oncology Pipeline

3 days ago talkbio0Tagged Antibody-Drug Conjugates, BioNTech, DualityBio, HER2-positive carcinoma of breast, Market, Oncology Pipeline, pamirtecan, Phase 3 trial, Progression-Free Survival, trastuzumab

BioNTech; DualityBio; antibody-drug conjugate (ADC); HER2-positive breast cancer; trastuzumab pamirtecan; BNT323/DB-1303; phase 3 trial; progression-free survival; oncology pipeline; ADC market

RFK Jr. Blasts Pharma Industry and Spreads mRNA Vaccine Misinformation During Heated Senate Hearing

6 days ago talkbio0Tagged Centers for Disease Control and Prevention (U.S.), COVID19 (disease), Leadership, mRNA misinformation, Pharma Industry, Policy, public health medicine (field), RFK Jr., Senate hearing, Vaccines

RFK Jr.; Senate hearing; pharma industry; mRNA misinformation; COVID-19 vaccines; public health; vaccine policy; CDC leadership

MRM Health Nets $64M and Treeline Gathers $200M: Fierce Biotech Fundraising Tracker 2025

6 days ago talkbio0Tagged Biocodex, Biotech Fundraising, Inflammatory Bowel Diseases, LBP, Live Biotherapeutic Product, Microbiome therapeutics, MRM Health, Series B funding, Treeline, Ulcerative Colitis

MRM Health; Series B Funding; Microbiome therapeutics; Ulcerative colitis; Live Biotherapeutic Product (LBP); Biocodex; Treeline; Biotech fundraising; IBD therapy